Latest News on ADMA

Financial News Based On Company


Advertisement
Advertisement

Form 144 ADMA BIOLOGICS For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-adma-biologics-for-16-november-93CH-5708519
Investing.com reported the filing of Form 144 for ADMA Biologics on November 16. This brief announcement includes the stock symbol ADMA and its daily performance, indicating a 1.19% increase. The article provides only this essential information without further elaboration.

Form 4 ADMA Biologics Inc: Lawrence P. Guiheen (Director) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-adma-biologics-inc-lawrence-p-guiheen-director-for-16-november-93CH-5708528
This article reports on a Form 4 filing for ADMA Biologics Inc, indicating an insider transaction by Director Lawrence P. Guiheen on November 16. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders.

Form 4 ADMA Biologics Inc: Adam S. Grossman (Director, President and CEO) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-adma-biologics-inc-adam-s-grossman-director-president-and-ceo-for-16-november-93CH-5708521
This article from Investing.com announces the filing of a Form 4 for ADMA Biologics Inc, detailing the insider transaction activities of Adam S. Grossman, who serves as Director, President, and CEO. The filing is specific to November 16th. The article provides a direct, unadorned statement of this regulatory disclosure without further details on the nature of the transactions.

Director Lawrence P. Guiheen proposes selling 10,000 ADMA Biologics (ADMA) shares.

https://www.stocktitan.net/sec-filings/ADMA/144-adma-biologics-inc-sec-filing-0704817e7a67.html
Lawrence P. Guiheen, a director at ADMA Biologics, has proposed selling 10,000 common shares of the company, valued at $136,800, with an approximate sale date of November 16, 2026. Guiheen acquired these shares by exercising stock options granted on February 14, 2017, using cash as the payment method. This transaction is detailed in an SEC Form 144 filing.

ADMA Biologics (ADMA) CEO exercises 15,000 options and sells 21,000 shares.

https://www.stocktitan.net/sec-filings/ADMA/form-4-adma-biologics-inc-insider-trading-activity-7ca3a691f7ff.html
ADMA Biologics President and CEO Adam S. Grossman exercised options for 15,000 common shares at $5.40 each and subsequently sold 21,000 common shares at $13.72 per share on November 16, 2026. These transactions were executed under a Rule 10b5-1 trading plan established on November 14, 2025. Following these transactions, Grossman's direct holdings include 2,064,777 common shares and 570,950 stock options.
Advertisement

More than 5% of ADMA Biologics (ADMA) was held by State Street as of September 30.

https://www.stocktitan.net/sec-filings/ADMA/schedule-13g-adma-biologics-inc-passive-investment-disclosure-5-b0e55c9703e4.html
State Street Corporation reported a beneficial ownership of 13,675,348 shares, or 6.1%, of ADMA Biologics, Inc. common stock as of September 30, 2026. This ownership includes shared voting power over 12,892,596 shares and shared dispositive power over 13,675,348 shares. The filing, a SCHEDULE 13G, indicates a passive investment.

Form SCHEDULE 13G ADMA BIOLOGICS, INC. Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+ADMA+BIOLOGICS%2C+INC.+Filed+by%3A+STATE+STREET+CORP/27317928.html
STATE STREET CORPORATION has filed a Schedule 13G form with the SEC, reporting its beneficial ownership in ADMA BIOLOGICS INC common stock. The filing indicates that State Street Corporation holds 13,675,348 shares, representing 6.1% of the class. This ownership includes shared voting power over 12,892,596 shares and shared dispositive power over 13,675,348 shares.

Results: ADMA Biologics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/results-adma-biologics-inc-exceeded-expectations-and-the-con
ADMA Biologics (NASDAQ:ADMA) reported strong third-quarter results, with revenues of US$141m and statutory earnings per share exceeding analyst expectations. Despite this beat, analysts have slightly downgraded their 2027 EPS forecasts, though revenue estimates remain stable. The consensus price target of US$17.00 for the stock remains unchanged, suggesting that the intrinsic value of the business is not seen as significantly altered by the revised earnings projections.

Canaccord Genuity Keeps Their Buy Rating on ADMA Biologics (ADMA)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8698345/canaccord-genuity-keeps-their-buy-rating-on-adma-biologics-adma/
Canaccord Genuity analyst Gary Nachman has reiterated a Buy rating on ADMA Biologics (ADMA), setting a price target of $19.00. This aligns with a Moderate Buy consensus rating from other analysts, also with an average price target of $19.00. The company recently reported strong financial results for the quarter ending June 30, with increased revenue and net profit compared to the previous year.

A director at ADMA Biologics (ADMA) lists 189,000 shares worth $1.98M for sale.

https://www.stocktitan.net/sec-filings/ADMA/144-adma-biologics-inc-sec-filing-1f4cb1b8c294.html
Adam S. Grossman, a director and officer at ADMA Biologics, has filed a notice to sell 189,000 common shares with an aggregate market value of $1,980,720. The proposed sales cover shares acquired or to be acquired through stock-option exercises and restricted stock unit vesting, with some sales already effected on November 5, 2026, and others planned over the subsequent 90-day period. The filing provides details on the securities, acquisition dates, and nature of payment.
Advertisement

Mizuho raises ADMA Biologics stock price target on ASCENIV growth

https://www.investing.com/news/analyst-ratings/mizuho-raises-adma-biologics-stock-price-target-on-asceniv-growth-93CH-5002890
Mizuho has increased its price target for ADMA Biologics (NASDAQ:ADMA) to $18.00 from $17.00, maintaining an Underperform rating, following ADMA Biologics' strong third-quarter revenue that surpassed expectations by $3 million. This growth was fueled by a 31% increase in ASCENIV sales and a favorable product mix shift, which resulted in a record gross margin of 70.8% and adjusted EBITDA of $77 million, exceeding Street estimates. The company also plans to present real-world outcomes data for ASCENIV and is accelerating the development of SG-001 using AI models.

ADMA Biologics (ADMA) CEO Grossman sold 147,000 shares for $1.76M at $12.00 under a 10b5-1 plan

https://www.quantisnow.com/insight/president-and-ceo-grossman-adam-s-exercised-105000-shares-at-6777631
ADMA Biologics CEO Adam Grossman sold 147,000 shares for $1.76 million at $12.00 per share and acquired 105,000 shares at $5.40, according to a Form 4 filing on November 5, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Following these trades, Grossman directly holds 2,070,777 shares.

Why Is ADMA Biologics Stock Soaring Thursday? - ADMA Biologics (NASDAQ:ADMA)

https://www.benzinga.com/trading-ideas/movers/26/11/62929362/adma-biologics-ceo-says-star-drug-asceniv-is-just-getting-started
ADMA Biologics Inc. (NASDAQ: ADMA) stock rose significantly on Thursday following better-than-expected third-quarter 2026 results, driven by strong demand and increased adoption of its drug ASCENIV. While ASCENIV's revenue grew 31% year over year, the company's BIVIGAM treatment faced pricing pressure, though demand showed signs of stabilizing. ADMA is also advancing an experimental pneumococcal infection treatment, SG001, utilizing its AI platform ADMAlytics, and received a raised price target from Cantor Fitzgerald.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

https://www.benzinga.com/trading-ideas/movers/26/11/62911502/12-health-care-stocks-moving-thursday-s-pre-market-session
This article identifies 12 healthcare stocks experiencing significant movement during Thursday's pre-market session, categorized into gainers and losers. Several companies, including ADMA Biologics, CareCloud, and Veracyte, saw their stock prices react to recent Q3 earnings reports. The report details the percentage change and market capitalization for each listed stock.

ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why

https://www.benzinga.com/markets/equities/26/11/62903160/adma-biologics-adma-shares-jump-28-after-hours-heres-why
ADMA Biologics Inc. (NASDAQ: ADMA) saw its shares jump over 28% in after-hours trading following the release of strong third-quarter 2026 results. The biopharmaceutical company reported a 5% year-over-year revenue increase and raised its full-year earnings guidance. Key drivers included a significant rise in ASCENIV revenue and constructive FDA feedback for an investigational new drug candidate.
Advertisement

ADMA Biologics Q3FY26 Results: Revenue up 5% YoY to $141.1 million

https://scanx.trade/stock-market-news/companies/adma-biologics-q3fy26-results-revenue-up-5-yoy-141-1-million/55383782
ADMA Biologics reported a 5% year-over-year revenue increase to $141.1 million in Q3FY26, primarily driven by a 31% surge in ASCENIV sales. This strong performance led to a 28% jump in shares after-hours, with adjusted EBITDA climbing 32% to $77.3 million due to expanded gross margins and improved efficiency. The company also raised its minimum adjusted EBITDA guidance for FY26 to $275 million.

$125M in borrowing funded a buyback at ADMA Biologics (ADMA) as quarterly profit rose.

https://www.stocktitan.net/sec-filings/ADMA/10-q-adma-biologics-inc-quarterly-earnings-report-edc369fb4a07.html
ADMA Biologics reported increased third-quarter 2026 profit of $49.9 million, up from $36.4 million a year earlier, with revenue rising to $141.1 million. This growth was primarily driven by a 30.7% increase in ASCENIV sales, while BIVIGAM sales decreased due to market competition. The company also funded a $125 million accelerated share repurchase program using its JPMorgan revolving credit facility, contributing to a significant increase in total debt.

ADMA Biologics Inc earnings beat by $0.03, revenue topped estimates

https://www.investing.com/news/earnings/adma-biologics-inc-earnings-beat-by-003-revenue-topped-estimates-5001449
ADMA Biologics Inc (ADMA) reported strong third-quarter results, beating analyst estimates with an EPS of $0.2300, $0.03 higher than predicted, and revenue of $141.1M, exceeding the consensus of $138.12M. The company's stock closed at $10.48, showing a 5.86% increase over the last three months, though it has declined by 31.82% over the past year. InvestingPro rates ADMA Biologics Inc's financial health as "great performance."

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/adma-biologics-reports-third-quarter-2026-financial-results-and-provides-business-update/2462213
ADMA Biologics announced strong third-quarter 2026 financial results, with total revenue up 5% year-over-year to $141.1 million and GAAP net income increasing 37% to $49.9 million. The growth was primarily driven by a 31% increase in ASCENIV revenue, alongside expanding gross margins and robust cash generation. The company also provided an update on its SG-001 development program, having received encouraging regulatory feedback from the FDA.

ADMA Biologics Beats On ASCENIV Acceleration And Margin Strength, But Floor-Level Revenue Guidance And Slower Cash Conversion Temper The Quarter

https://finviz.com/news/416328/adma-biologics-beats-on-asceniv-acceleration-and-margin-strength-but-floor-level-revenue-guidance-and-slower-cash-conversion-temper-the-quarter
ADMA Biologics exceeded third-quarter earnings and revenue expectations, driven by strong growth in its specialty immune globulin, ASCENIV, and improved gross margins. Despite the profit strength and regulatory traction for a new investigational drug, the company's decision to maintain floor-level revenue guidance and issues like rising receivables and debt-funded buybacks left investors cautious. The report confirmed Q1 as a trough, but several financial ambiguities persist.
Advertisement

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/04/3395815/33130/en/adma-biologics-reports-third-quarter-2026-financial-results-and-provides-business-update.html
ADMA Biologics announced strong third-quarter 2026 financial results, with total revenue up 5% year-over-year to $141.1 million, driven by a 31% increase in ASCENIV revenue. The company also raised its full-year 2026 adjusted earnings outlook and provided a positive update on its SG-001 investigational hyperimmune globulin candidate, including constructive FDA feedback on its pre-IND package.

Earnings To Watch: ADMA Biologics Inc (ADMA) Q3 2026 -- GF Value Sees 102% Upside

https://finance.yahoo.com/healthcare/articles/earnings-watch-adma-biologics-inc-123655369.html
ADMA Biologics Inc (NASDAQ:ADMA) is slated to release its Q3 2026 earnings on November 4, 2026, with revenue estimated at $138.19 million and earnings at $0.2 per share. While estimates have seen a slight decline over the past 90 days, the average analyst price target suggests a 53.71% upside, and GuruFocus's GF Value indicates a potential 101.72% upside from its current price. The stock's average brokerage recommendation stands at "Outperform."

ADMA Biologics Inc (ADMA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6363_QuantitativeReport_1793145600000
Argus has raised its target price for ADMA Biologics Inc (ADMA) to $12.00, with the stock currently trading at $11.41. ADMA Biologics is a commercial biopharmaceutical company focused on developing and manufacturing plasma-derived biologics for immunodeficient patients and those at risk of infectious diseases. The report was published on October 28, 2026.

ADMA Biologics, Inc. (ADMA) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ADMA/seasonality/
This article provides a seasonality chart for ADMA Biologics, Inc. (ADMA), displaying average monthly price returns from 2016 to 2026. The financial data includes real-time and after-hours stock prices, showing a slight decrease. It also lists related tickers and various market indices.

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

https://www.globenewswire.com/news-release/2026/10/28/3390004/33130/en/adma-biologics-to-report-third-quarter-2026-financial-results-on-november-4-2026.html
ADMA Biologics, Inc. announced it will report its third-quarter 2026 financial results on November 4, 2026, after the U.S. financial markets close. The company's management team will host a live conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results and other company updates. Participants are encouraged to register in advance for the call.
Advertisement

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

https://finance.yahoo.com/healthcare/articles/adma-biologics-report-third-quarter-110000065.html
ADMA Biologics, Inc. announced it will report its third quarter 2026 financial results on November 4, 2026, after the U.S. financial markets close. The company's management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss the results and provide company updates. Participants are required to register for the call to receive dial-in information.

ADMA Biologics Inc (ADMA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6363_QuantitativeReport_1792540800000
Argus has raised its target price for ADMA Biologics Inc (ADMA) to $11.00. ADMA Biologics is a commercial biopharmaceutical company focused on developing and marketing specialty plasma-derived biologics for immunodeficient patients and those at risk for infectious diseases. The current price of ADMA stock is reported as $11.28.

ADMA Biologics Inc Estimates – NASDAQ:ADMA

https://www.tradingview.com/symbols/NASDAQ-ADMA/financials-estimates/
This article provides access to financial actuals and analyst estimates for ADMA Biologics Inc (NASDAQ: ADMA) through TradingView. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.

ADMA Biologics Inc (ADMA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6363_QuantitativeReport_1791936000000
The article "ADMA Biologics Inc (ADMA) Stock Forecasts" from Yahoo Finance appears to have encountered an error in retrieving data. As a result, it does not provide any specific content regarding ADMA Biologics' stock forecasts or related financial information. The page mainly consists of navigation elements and market data for Canada.

Could ADMA Biologics' New IVIG Data Be A Catalyst For Investor Interest?

https://www.rttnews.com/3699369/could-adma-biologics-new-ivig-data-be-a-catalyst-for-investor-interest.aspx
ADMA Biologics announced the publication of peer-reviewed findings detailing its optimized intravenous immune globulin (IVIG) manufacturing process. The study, published in Frontiers in Cardiovascular Medicine, indicates the process effectively removes impurities linked to thromboembolic risk while preserving immunoglobulin quality and boosting IgG yield. The article aims to explore these findings and the context of IVIG therapy and its manufacturing challenges.
Advertisement

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

https://finance.yahoo.com/healthcare/articles/adma-biologics-announces-peer-reviewed-110000303.html
ADMA Biologics has announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine, detailing new data from its optimized IVIG manufacturing process. The study found that ADMA's process effectively removes procoagulant impurities, which are associated with thrombosis risk, while maintaining immunoglobulin quality and increasing IgG yield. Furthermore, no thromboembolic events were reported for ADMA's IVIG products manufactured using this optimized process during the evaluated postmarketing surveillance period.

ADMA Biologics Announces Peer-Reviewed Publication

https://www.globenewswire.com/news-release/2026/10/15/3381479/33130/en/adma-biologics-announces-peer-reviewed-publication-highlighting-new-data-from-its-optimized-proprietary-ivig-manufacturing-process.html
ADMA Biologics announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine, detailing new data from its optimized IVIG manufacturing process. The study highlights the process's effectiveness in removing procoagulant impurities, maintaining immunoglobulin quality, and increasing IgG yield, with no reported thromboembolic events in postmarketing surveillance. These findings support the differentiated quality profile of ADMA's IVIG portfolio and its commitment to advancing manufacturing science for immune-compromised patients.

ADMA Biologics Announces Peer-Reviewed Publication

https://www.globenewswire.com/news-release/2026/10/15/3381479/0/en/adma-biologics-announces-peer-reviewed-publication-highlighting-new-data-from-its-optimized-proprietary-ivig-manufacturing-process.html
ADMA Biologics announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from its optimized IVIG manufacturing process. The study found that the optimized process effectively removed procoagulant impurities while maintaining immunoglobulin quality, increasing IgG yield, and showing no reported thromboembolic events in postmarketing surveillance. This reinforces the safety and quality profile of ADMA's IVIG products for immune-compromised patients.

QFIN HOLDINGS, INC. (QFIN) SHAREHOLDER ALERT Bernstein

https://www.globenewswire.com/news-release/2026/10/13/3379809/0/en/qfin-holdings-inc-qfin-shareholder-alert-bernstein-liebhard-llp-reminds-adma-biologics-inc-investors-of-upcoming-deadline.html
Bernstein Liebhard LLP has issued a shareholder alert for QFIN Holdings, Inc. (QFIN) investors, reminding them of an upcoming November 27, 2026, deadline for a securities fraud class action lawsuit. The lawsuit alleges that Qfin made materially false and misleading statements about its business and financial stability between March 18, 2026, and August 25, 2026, causing investors to suffer losses. Investors who purchased QFIN shares during this period are encouraged to act promptly and consider joining the class action.

ADMA Biologics Inc (ADMA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6363_QuantitativeReport_1791331200000
Argus has raised its target price for ADMA Biologics Inc (ADMA) to $10.00. The company is a commercial biopharmaceutical firm focused on developing plasma-derived biologics for immunodeficient patients. The current stock price for ADMA is $10.36.
Advertisement

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

https://uk.finance.yahoo.com/news/adma-biologics-adma-advances-while-205002814.html
Adma Biologics (ADMA) saw a 1.87% increase in its stock price, outperforming the S&P 500, Dow, and Nasdaq in the latest trading session. The company is anticipated to report an 18.75% rise in EPS and 4.16% revenue growth for its upcoming earnings, with analysts maintaining a "Hold" rating. ADMA's current Forward P/E ratio of 13.06 suggests it is undervalued compared to its industry average.

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

https://finance.yahoo.com/markets/stocks/articles/heres-why-adma-biologics-adma-204505856.html
Adma Biologics (ADMA) saw its stock fall by 1.24% in the latest trading session, underperforming the broader market. The company is anticipated to announce earnings of $0.19 per share and revenue of $139.8 million in its upcoming report, reflecting significant year-over-year growth. Analysts' revisions to forecasts and the company's current Zacks Rank of #3 (Hold) and attractive Forward P/E ratio are key factors for investors to monitor.

ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

https://www.easternprogress.com/adma-biologics-inc-adma-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit/article_dda196b1-02a7-5f7a-bcdd-338424da858d.html
The Law Offices of Howard G. Smith announced that investors who suffered losses in ADMA Biologics, Inc. (ADMA) have an opportunity to lead a securities fraud class action lawsuit. The complaint alleges that ADMA engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls, leading to materially misleading statements to investors between August 9, 2024, and March 25, 2026. Affected shareholders are encouraged to contact the firm before the August 10, 2026, lead plaintiff deadline.

ADMA Biologics, Inc. (ADMA) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/ADMA/
This Yahoo Finance page provides a detailed overview of ADMA Biologics, Inc. (ADMA) stock. It includes real-time stock price data, pre-market and after-hours trading information, key financial metrics, and charting tools. The page also offers various financial data points like market capitalization, price ranges, and links to recent news and company insights.

(ADMA) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/151/ADMA_Price_Dynamics_and_Execution-Aware_Positioning_092526060002_1790330402.html
This article analyzes Adma Biologics Inc (NASDAQ: ADMA) price dynamics, highlighting a near-term positive sentiment that may shift and a broader weak alignment. It identifies an exceptional risk-reward short setup with a 26.5% downside target and outlines three AI-generated institutional trading strategies for different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels for near-term, mid-term, and long-term horizons.
Advertisement

ADMA Biologics Inc - Common Stock (Nasdaq:ADMA) Price Chart

https://markets.chroniclejournal.com/observerreporter/quote/chart?Symbol=NQ%3AADMA
This page displays the current stock price and basic market data for ADMA Biologics Inc (Nasdaq: ADMA). It shows the real-time stock quote, percentage change, and the time of the last update. The article provides a quick overview of the company's stock performance.

Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know

https://finance.yahoo.com/markets/stocks/articles/adma-biologics-adma-falls-more-215001256.html
Adma Biologics (ADMA) experienced a significant drop in its stock price, falling 1.01% at the latest close, underperforming major market indices like the S&P 500, Dow, and Nasdaq. The company is projected to report strong earnings and revenue growth for its upcoming release and the full fiscal year, with positive analyst estimate revisions suggesting a favorable business outlook. Despite a Zacks Rank of #3 (Hold), its Forward P/E ratio indicates a discount compared to its industry average within the Medical - Biomedical and Genetics sector.

Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?

https://finance.yahoo.com/healthcare/articles/adma-biologics-adma-down-4-153011478.html
Adma Biologics (ADMA) shares have dropped 4.8% since its last earnings report, underperforming the S&P 500, but the company's Q2 2026 earnings matched estimates, with revenues missing slightly due to Bivigam weakness despite strong Asceniv growth. The company reiterated its full-year 2026 guidance and continued share repurchases, while advancing its SG-001 hyperimmune globulin program.

Trading Systems Reacting to (ADMA) Volatility

https://news.stocktradersdaily.com/news_release/9/Trading_Systems_Reacting_to_ADMA_Volatility_090426120601_1788537961.html
This article from Stock Traders Daily discusses the volatility of Adma Biologics Inc (NASDAQ: ADMA), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis, indicating neutral to weak sentiment across different horizons. The piece emphasizes the platform's AI models for optimizing position sizing and managing risk for investors.

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

https://www.newsfilecorp.com/release/311503/ADMA-BIOLOGICS-INC.-ADMA-SHAREHOLDER-INVESTIGATION-ALERT-Bernstein-Liebhard-Investigates-Potential-Breaches-of-Fiduciary-Duty
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. (NASDAQ: ADMA). The firm is seeking to determine if the Company's leadership upheld its obligations to shareholders, especially those who purchased shares before August 9, 2024. Shareholders are encouraged to contact Bernstein Liebhard LLP to discuss their legal rights.
Advertisement

ADMA Biologics (ADMA) After Strong Q2 Results And Reaffirmed Guidance Is It A Bargain

https://www.sahmcapital.com/news/content/adma-biologics-adma-after-strong-q2-results-and-reaffirmed-guidance-is-it-a-bargain-2026-08-19
ADMA Biologics (ADMA) reported strong Q2 2026 results with $124.4 million in sales and $37.82 million in net income, reaffirming full-year revenue guidance. Despite a year-to-date share price drop, the stock has seen positive short-term returns and a significant 5-year total shareholder return. Analysts believe the company is 46% undervalued with a fair value of $17.60, contingent on successful execution and avoiding setbacks.

Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty

https://pluang.com/en/news-feed/investigasi-pelanggaran-tugas-fidusia-adma-biologics
Bernstein Liebhard LLP is investigating whether ADMA Biologics' directors and officers breached their fiduciary duties to shareholders, potentially leading to legal action. This probe follows another investigation by Berger Montague PC into alleged revenue inflation through channel-stuffing practices. Shareholders who purchased ADMA shares before August 9, 2024, are encouraged to contact the firm.

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

https://www.newsfilecorp.com/release/310258/ADMA-BIOLOGICS-INC.-ADMA-SHAREHOLDER-INVESTIGATION-ALERT-Bernstein-Liebhard-Investigates-Potential-Breaches-of-Fiduciary-Duty
Bernstein Liebhard LLP has launched an investigation into potential breaches of fiduciary duty by directors and officers of ADMA Biologics, Inc. (NASDAQ: ADMA). The firm is seeking to determine if the company's leadership has fulfilled its obligations to shareholders and whether legal remedies are available. Current ADMA shareholders, particularly those who purchased shares before August 9, 2024, are encouraged to contact Bernstein Liebhard for a confidential consultation.

Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-holdings-in-adma-biologics-inc-adma-2026-08-15/
Bank of America Corp DE significantly increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 107.5% in the first quarter, now owning 3.998 million shares valued at $36 million. Other institutional investors like Sachem Head, Westfield Capital, and Capital Research also raised their holdings, contributing to the high institutional ownership of 75.68%. While analyst sentiment is mixed with a "Hold" rating and a consensus price target of $18.67, ADMA Biologics matched its quarterly EPS estimates and reported a 2% year-over-year revenue increase.

Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum

https://www.sahmcapital.com/news/content/why-adma-biologics-adma-is-up-56-after-reaffirming-2026-revenue-guidance-and-eps-momentum-2026-08-13
ADMA Biologics reaffirmed its full-year 2026 revenue guidance of US$530 million to US$560 million after reporting solid Q2 2026 results. The company's performance, including higher quarterly and year-to-date EPS, indicates management confidence despite a previous, more bullish guidance reset. The article highlights the importance of production scaling, yield efficiency, and plasma availability to ADMA's investment narrative, which projects significant revenue and earnings growth by 2029.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement